Telix Historical Cash Flow

TLX Stock

24.74 0.93 3.62%

Analysis of Telix Pharmaceuticals cash flow over time is an excellent tool to project Telix Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 11.3 M or Total Cash From Operating Activities of 25.1 M as it is a great indicator of Telix Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Telix Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Telix Pharmaceuticals is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Telix Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Telix balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Telix's non-liquid assets can be easily converted into cash.

Telix Pharmaceuticals Cash Flow Chart

At this time, Telix Pharmaceuticals' Stock Based Compensation is comparatively stable compared to the past year. Free Cash Flow is likely to gain to about 13.7 M in 2024, despite the fact that Total Cashflows From Investing Activities is likely to grow to (14.5 M).

Change In Cash Capital Expenditures Net Income Change To Netincome Stock Based Compensation Change In Working Capital

Capital Expenditures

Capital Expenditures are funds used by Telix Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Telix Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Telix Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Telix Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Change In Working Capital

The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.

Most accounts from Telix Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Telix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Telix Pharmaceuticals cash flow statement Correlations

	Sale Purchase Of Stock	Change In Cash	Net Borrowings	Depreciation	Other Non Cash Items	Capital Expenditures	Change To Account Receivables	Change To Operating Activities	Net Income	Change To Netincome	Change To Inventory	Investments	Stock Based Compensation	Free Cash Flow	Change In Working Capital	Begin Period Cash Flow	Dividends Paid	End Period Cash Flow	Issuance Of Capital Stock
Sale Purchase Of Stock		0.37	-0.57	-0.71	-0.76	-0.63	0.68	0.38	0.47	-0.69	0.63	0.64	-0.68	0.23	0.35	-0.73	-0.6	-0.45	-0.05
Change In Cash	0.37		0.07	-0.35	-0.36	0.07	0.22	-0.37	0.07	-0.16	0.23	0.12	-0.06	0.03	0.29	-0.65	-0.27	0.38	0.68
Net Borrowings	-0.57	0.07		0.7	0.88	0.97	-0.95	-0.84	-0.13	0.93	-0.94	-0.98	0.97	0.0	-0.78	0.67	0.86	0.82	0.19
Depreciation	-0.71	-0.35	0.7		0.92	0.76	-0.81	-0.34	-0.46	0.89	-0.82	-0.79	0.85	-0.17	-0.51	0.86	0.79	0.61	-0.06
Other Non Cash Items	-0.76	-0.36	0.88	0.92		0.89	-0.96	-0.56	-0.3	0.97	-0.96	-0.94	0.95	-0.09	-0.74	0.92	0.91	0.65	-0.07
Capital Expenditures	-0.63	0.07	0.97	0.76	0.89		-0.94	-0.79	-0.34	0.94	-0.91	-0.95	0.97	-0.21	-0.67	0.65	0.86	0.81	0.34
Change To Account Receivables	0.68	0.22	-0.95	-0.81	-0.96	-0.94		0.72	0.2	-0.95	0.97	0.99	-0.96	0.07	0.83	-0.83	-0.89	-0.7	-0.05
Change To Operating Activities	0.38	-0.37	-0.84	-0.34	-0.56	-0.79	0.72		-0.1	-0.61	0.65	0.77	-0.76	-0.16	0.58	-0.33	-0.45	-0.78	-0.39
Net Income	0.47	0.07	-0.13	-0.46	-0.3	-0.34	0.2	-0.1		-0.33	0.12	0.12	-0.26	0.9	-0.31	-0.16	-0.33	-0.2	-0.56
Change To Netincome	-0.69	-0.16	0.93	0.89	0.97	0.94	-0.95	-0.61	-0.33		-0.97	-0.95	0.97	-0.13	-0.71	0.81	0.94	0.75	0.07
Change To Inventory	0.63	0.23	-0.94	-0.82	-0.96	-0.91	0.97	0.65	0.12	-0.97		0.98	-0.95	-0.04	0.86	-0.85	-0.93	-0.7	0.09
Investments	0.64	0.12	-0.98	-0.79	-0.94	-0.95	0.99	0.77	0.12	-0.95	0.98		-0.98	-0.03	0.83	-0.8	-0.88	-0.77	-0.04
Stock Based Compensation	-0.68	-0.06	0.97	0.85	0.95	0.97	-0.96	-0.76	-0.26	0.97	-0.95	-0.98		-0.06	-0.71	0.77	0.86	0.81	0.16
Free Cash Flow	0.23	0.03	0.0	-0.17	-0.09	-0.21	0.07	-0.16	0.9	-0.13	-0.04	-0.03	-0.06		-0.3	0.07	-0.22	0.02	-0.64
Change In Working Capital	0.35	0.29	-0.78	-0.51	-0.74	-0.67	0.83	0.58	-0.31	-0.71	0.86	0.83	-0.71	-0.3		-0.71	-0.75	-0.42	0.32
Begin Period Cash Flow	-0.73	-0.65	0.67	0.86	0.92	0.65	-0.83	-0.33	-0.16	0.81	-0.85	-0.8	0.77	0.07	-0.71		0.77	0.39	-0.39
Dividends Paid	-0.6	-0.27	0.86	0.79	0.91	0.86	-0.89	-0.45	-0.33	0.94	-0.93	-0.88	0.86	-0.22	-0.75	0.77		0.57	-0.01
End Period Cash Flow	-0.45	0.38	0.82	0.61	0.65	0.81	-0.7	-0.78	-0.2	0.75	-0.7	-0.77	0.81	0.02	-0.42	0.39	0.57		0.38
Issuance Of Capital Stock	-0.05	0.68	0.19	-0.06	-0.07	0.34	-0.05	-0.39	-0.56	0.07	0.09	-0.04	0.16	-0.64	0.32	-0.39	-0.01	0.38

Click cells to compare fundamentals

Telix Pharmaceuticals Account Relationship Matchups

Telix Pharmaceuticals cash flow statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Sale Purchase Of Stock	45.3M	(130K)	3.8M	(7.8M)	(7.0M)	(6.7M)
Change In Cash	18.8M	33.3M	(55.9M)	94.3M	6.9M	6.6M
Net Borrowings	(1.2M)	(904K)	(936K)	1.7M	2.0M	2.1M
Total Cashflows From Investing Activities	(468K)	(1.1M)	(2.7M)	(17.0M)	(15.3M)	(14.5M)
Other Cashflows From Financing Activities	(1.6M)	(502K)	(596K)	(1.3M)	(2.2M)	(2.3M)
Depreciation	4.2M	4.9M	5.2M	5.4M	6.9M	7.3M
Other Non Cash Items	9.7M	18.7M	31.5M	41.0M	60.5M	63.5M
Capital Expenditures	468K	322K	1.3M	13.9M	10.8M	11.3M
Total Cash From Operating Activities	(23.3M)	2.0M	(59.3M)	(64.0M)	23.9M	25.1M
Change To Account Receivables	(3.6M)	(328K)	(7.2M)	(19.9M)	(27.4M)	(26.0M)
Change To Operating Activities	198K	(193K)	2.6M	(3.7M)	(3.3M)	(3.2M)
Net Income	(27.9M)	(44.9M)	(80.5M)	(104.1M)	5.2M	5.5M
Total Cash From Financing Activities	42.7M	34.1M	2.8M	175.0M	10.2M	9.7M
Change To Netincome	659K	10.2M	18.6M	35.7M	41.1M	43.2M
Change To Liabilities	3.0M	32.4M	4.8M	27.6M	31.8M	33.4M
Investments	(468K)	(1.1M)	(2.7M)	(17.0M)	(25.5M)	(24.2M)
Stock Based Compensation	1.3M	2.3M	1.3M	8.1M	8.8M	9.2M
Free Cash Flow	(23.8M)	1.6M	(60.7M)	(77.8M)	13.1M	13.7M
Change In Working Capital	(361K)	31.8M	(2.6M)	(1.0M)	(57.5M)	(54.7M)
Begin Period Cash Flow	25.8M	44.6M	77.9M	22.0M	116.3M	122.1M
End Period Cash Flow	44.6M	77.9M	22.0M	116.3M	123.2M	72.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Telix Stock Analysis

When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC